Beta Drugs Ltd
|
info@betadrugslimited.com Website:www.betadrugslimited.com
|
Public issue of 22,96,000 equity shares of face value of Rs. 10/- each ("equity shares") of Beta Drugs Limited (the "company" Or the "issuer") for cash at a price of Rs. 85/- per equity share, including a share premium of Rs. 75/- per equity share (the "issue price"), aggregating Rs. 19.52 crores ("the issue"), of which 1,29,600 equity shares of face value of Rs. 10/- each for Cash at a price of Rs. 85/- per equity share, aggregating Rs. 1.10 crores will be reserved for subscription by the market Maker to the issue (the "market maker reservation portion"). The issue less market maker reservation portion i.e. Issue of 21,66,400 equity shares of face value of Rs. 10 each for cash at a price of Rs. 85/- per equity share, aggregating
Rs. 18.42 crores is hereinafter referred to as the "net issue". The issue and the net issue will constitute 26.54% and 25.05% Respectively of the fully diluted post issue paid up equity share capital of the company.
The face value of the equity shares is Rs. 10 each and the issue price of Rs. 85 is 8.5 times of the face value of the Equity shares.
|
|
|
|
|
Beta Drugs Ltd
|
|
Rs Cr |
Lead Managers to the Issue |
19.52 |
Pantomath Capital Advisors Pvt Ltd |
|
19.52 |
|
8.65 |
|
Rs.
85.00
|
|
|
|
|
|
Projects |
Purchase of new plant and machinery and upgradition of the existing plant and machinery
|
Civil construction work at existing manufacturing plant
|
To obtain registration of european union GMP & Pharmaceutical Inspection Co-operation scheme
|
Working capital
|
General Corporate Purpose
| |
|
|
|
|
Link Intime India Pvt Ltd |
|
|
|
|